Quick Answer
BioNexus Gene Lab Corp reported Common Stock Shares Outstanding of 17.97 million shares for the year ending 2024.
- BioNexus Gene Lab Corp showed an increase of +1.7% in Common Stock Shares Outstanding from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: 74.63 million shares | Q3 2019: 73.70 million shares | Q1 2020: 171.22 million shares | Q2 2020: 102.73 million shares | Q3 2020: 102.73 million shares | Q1 2021: 171.22 million shares | Q2 2021: 171.22 million shares | Q3 2021: 171.22 million shares | Q1 2022: 171.22 million shares | Q2 2022: 171.22 million shares | Q3 2022: 173.72 million shares | Q1 2023: 173.72 million shares | Q2 2023: 173.72 million shares | Q1 2024: 17.67 million shares | Q2 2024: 17.67 million shares | Q3 2024: 17.97 million shares | Q4 2024: 1.80 million shares | Q1 2025: 17.97 million shares | Q2 2025: 1.80 million shares | Q3 2025: 1.80 million shares.
- Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Common Stock Shares Outstanding has declined by 75.9%.
- Historical annual values: Fiscal year 2024: 17.97 million shares | Fiscal year 2023: 17.67 million shares | Fiscal year 2022: 14.48 million shares | Fiscal year 2021: 171.22 million shares | Fiscal year 2020: 171.22 million shares | Fiscal year 2019: 102.73 million shares | Fiscal year 2018: 74.63 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: